Prostate Cancer Treatment in Ahmedabad — Expert Uro-Oncology at EPIC Multispecialty Hospital
Prostate cancer is the second most common cancer in men worldwide and an increasingly significant oncological condition in Ahmedabad and Gujarat — partly reflecting improved diagnosis through PSA testing, and partly reflecting genuine rising incidence with urbanisation and changing metabolic profiles in the population. The challenge in prostate cancer management is not simply treating cancer that needs treatment — it is identifying which prostate cancers genuinely need treatment, which can be safely monitored without immediate intervention (active surveillance), and which require systemic treatment rather than local therapy.
At EPIC Multispecialty Hospital, Ahmedabad, prostate cancer treatment is delivered through a dedicated uro-oncology programme — with PSA-based and MRI-targeted biopsy for accurate diagnosis, multi-disciplinary tumour board review of every newly diagnosed prostate cancer, active surveillance for appropriate low-risk patients, radical prostatectomy (laparoscopic and robotic-assisted) for localised intermediate and high-risk disease, and systemic therapy (androgen deprivation, docetaxel, enzalutamide, abiraterone) for advanced and metastatic disease.
Patients with prostate cancer from across Gujarat — from Vadodara, Surat, Rajkot, Gandhinagar, Anand, Nadiad, and Bharuch — and from Rajasthan and Madhya Pradesh seek prostate cancer treatment at EPIC Multispecialty Hospital, Ahmedabad, where the spectrum of uro-oncological expertise — from active surveillance to robotic surgery to advanced systemic therapy — is available in one integrated programme.
Prostate Cancer Treatment at EPIC Multispecialty Hospital, Ahmedabad — Staging-Based Management
- Diagnosis — PSA, MRI, and targeted biopsy: Prostate-specific antigen (PSA) testing — a blood test measuring PSA, a protein produced by normal and malignant prostate cells — is the primary prostate cancer screening tool. Elevated PSA (above 4 ng/mL, or above 2.5 ng/mL in younger men, or rapidly rising PSA velocity) prompts further evaluation. MRI prostate (multiparametric MRI — mpMRI) before biopsy — the PROMIS and PRECISION trials demonstrated that mpMRI-targeted biopsy identifies more clinically significant cancers and fewer insignificant cancers than systematic TRUS biopsy. At EPIC Hospital Ahmedabad, mpMRI followed by MRI-TRUS fusion targeted biopsy (or cognitive fusion biopsy) is standard for patients with raised PSA and no previous biopsy.
- Active surveillance for low-risk prostate cancer: Low-risk prostate cancer (PSA below 10, Gleason grade group 1, clinical stage T1c to T2a) in older or comorbid patients, or intermediate-risk cancer in patients who prefer to avoid treatment side effects, can be managed with active surveillance — PSA monitoring every 3 to 6 months, repeat mpMRI every 12 to 24 months, and protocol biopsy at 1 year and every 3 to 5 years thereafter. Active surveillance avoids the morbidity of treatment (urinary incontinence, erectile dysfunction) for cancers that are unlikely to cause harm within the patient’s life expectancy. The ProtecT trial demonstrates equivalent 15-year prostate cancer-specific survival between active surveillance, radical prostatectomy, and radiotherapy for low-risk disease.
- Radical prostatectomy — laparoscopic and robotic: Radical prostatectomy — complete removal of the prostate and seminal vesicles — is the primary surgical treatment for localised prostate cancer (clinically confined to the prostate, intermediate and high-risk disease where cure is the intent and life expectancy is above 10 years). Laparoscopic radical prostatectomy provides 10 to 15-times magnification for precise neurovascular bundle dissection (potency preservation) and apical dissection (urinary continence). Robotic-assisted RALP adds 3D vision and wristed instrument articulation to laparoscopic advantages. At EPIC Multispecialty Hospital, Ahmedabad, laparoscopic and robotic radical prostatectomy are performed with nerve-sparing intent — bilateral, unilateral, or no nerve-sparing — based on pre-operative cancer risk and individual patient priorities for continence and potency.
- Radiation therapy for prostate cancer: External beam radiotherapy (EBRT) with or without androgen deprivation therapy (ADT) is an alternative to radical prostatectomy for localised prostate cancer — with equivalent cancer control in comparable risk groups. Stereotactic body radiotherapy (SBRT — 5 fractions) and conventional IMRT (40 to 45 fractions) are available. Brachytherapy — seed implantation (low-dose rate) or high-dose rate brachytherapy — is used for low-risk and selected intermediate-risk prostate cancer. Our radiation oncology team at EPIC Hospital Ahmedabad coordinates radiotherapy planning within the uro-oncology MDT.
- Advanced prostate cancer — hormone therapy and beyond: Locally advanced prostate cancer (T3 to T4 or N1) is treated with ADT (LHRH agonist — leuprolide, goserelin — or antagonist — degarelix, relugolix) plus radiotherapy or post-prostatectomy radiotherapy. Metastatic hormone-sensitive prostate cancer (mHSPC) is managed with combination ADT plus docetaxel chemotherapy or ADT plus novel androgen receptor pathway inhibitors (abiraterone, enzalutamide, apalutamide, darolutamide). Metastatic castration-resistant prostate cancer (mCRPC) is managed with docetaxel, cabazitaxel, enzalutamide, abiraterone, PARP inhibitors (olaparib for BRCA-mutated tumours), and Ra-223 for bone-dominant disease.
- Prostate cancer genetics — BRCA testing and counselling: Germline BRCA2 mutations are found in 5 to 7 percent of metastatic prostate cancers and confer eligibility for PARP inhibitor therapy (olaparib). Germline BRCA1, CHEK2, ATM, and Lynch syndrome mutations are also represented in prostate cancer. Genetic testing and counselling for metastatic prostate cancer patients, and cascade testing for family members, is coordinated through our oncogenetics service at EPIC Multispecialty Hospital, Ahmedabad.
Prostate Cancer Treatment in Ahmedabad — Active Surveillance vs Treatment Decision and What the Evidence Shows
The most consequential decision in prostate cancer management in Ahmedabad is not which treatment to choose — it is whether treatment is needed at all. A large proportion of men diagnosed with prostate cancer in Ahmedabad through opportunistic PSA testing have low-risk disease that poses minimal threat to their survival within their life expectancy, but whose treatment — whether surgery or radiotherapy — carries significant risks of urinary incontinence and erectile dysfunction that substantially impair quality of life. The ProtecT trial demonstrated that 10-year prostate cancer-specific mortality was under 2 percent regardless of whether patients received active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer — making quality of life, not survival, the primary decision variable for most low-risk and many intermediate-risk patients.
Active surveillance — the protocol of watchful monitoring with regular PSA tests, repeat mpMRI, and protocol biopsy to detect disease reclassification — avoids or delays treatment morbidity while maintaining cancer control through early detection of disease progression. At EPIC Multispecialty Hospital, Ahmedabad, we offer active surveillance as a genuine first-line option for appropriately selected patients, not as a fallback for patients who decline treatment. Men on active surveillance at EPIC Hospital Ahmedabad receive structured follow-up: PSA every 3 months in year 1, then 6-monthly; mpMRI at 12 months and every 24 months thereafter; repeat biopsy at 12 months. If grade group increases or PSA rises significantly, curative treatment is offered before the cancer has an opportunity to become metastatic.
For men who do require treatment for localised prostate cancer in Ahmedabad, the choice between radical prostatectomy and radiotherapy is genuinely a preference-sensitive decision — the oncological outcomes are comparable, but the side effect profiles differ: surgery carries higher early incontinence risk and lower late rectal toxicity; radiotherapy carries lower early continence impact but higher late bowel toxicity. Our uro-oncology team at EPIC Multispecialty Hospital, Ahmedabad, provides both options and supports patients through a structured decision-making process that explicitly addresses individual priorities for continence, erectile function, and long-term monitoring.
Know Your Signs
Unexplained weight loss
Loss of appetite
Easy bruising or unusual bleeding
Weakened immune system
Persistent fatigue or weakness
Persistent or unexplained pain
Pale skin or breathlessness
Bone or joint pain
Emergency Services
Our dedicated emergency team is available 24/7 to provide immediate medical care and support in critical situations.
Get In Touch
BOOK AN APPOINTMENT
Find Best Oncology, Haematology & Bone Marrow Transplant Hospital in Ahmedabad
Dedicated Day-Care Chemotherapy Unit
Multidisciplinary team approach
Complete cancer care under one roof - screening, diagnosis, treatment, transplant & follow-up
Highly experienced team of Oncologists, Hemato-Oncologists, and Blood Cancer & Transplant Experts
State-of-the-art infrastructure with Class 1000 Separate AHU (Air Handling Unit)
Strong focus on patient safety, strict infection control, and quality care
24×7 critical care support
Dedicated HEPA-filtered isolation rooms for BMT & immunocompromised patients
Our Team of Expert Doctors
DR. SANDIP SHAH
M.D., FELLOWSHIP IN MEDICAL ONCOLOGY
DR. SANKET SHAH
M.D., D.M., P.D.F.
Talks By Our Oncology, Haematology & Bone Marrow Transplant Expert Doctors
World Sickle Cell Awareness 23 by Dr. Ankit Raiyani, Haematologist & BoneMarrow Transplant Physician
Healthy life tips by Dr. Dhiren Parikh – EPIC Hospital Ahmedabad
Acute Erythroid Leukemia – Dr. Sandip Shah
Talks By Our Oncology, Haematology & Bone Marrow Transplant Expert Doctors
Acute Erythroid Leukemia – Dr. Sandip Shah
World Sickle Cell Awareness 23 by Dr. Ankit Raiyani, Haematologist & BoneMarrow Transplant Physician
Healthy life tips by Dr. Dhiren Parikh – EPIC Hospital Ahmedabad
Blogs By Our Oncology, Haematology & Bone Marrow Transplant Expert
Frequently Asked Questions — Prostate Cancer Treatment in Ahmedabad
What is PSA and how is prostate cancer diagnosed?
PSA (Prostate Specific Antigen) is a blood test used as a prostate cancer screening tool. Elevated or rapidly rising PSA prompts further evaluation with multiparametric MRI (mpMRI) of the prostate. MRI-targeted biopsy — under ultrasound guidance with MRI fusion — samples suspicious areas identified on mpMRI, achieving better detection of clinically significant cancer. At EPIC Multispecialty Hospital, Ahmedabad, mpMRI and MRI-targeted biopsy are standard for new PSA elevation.
What is active surveillance for prostate cancer and who is eligible?
Active surveillance monitors low-risk prostate cancer (Gleason grade group 1, PSA below 10, organ-confined) with regular PSA, repeat mpMRI, and protocol biopsy — treating only if disease progresses. It avoids immediate treatment morbidity (incontinence, erectile dysfunction) for cancers unlikely to cause harm in the patient’s lifetime. Our uro-oncology team at EPIC Hospital Ahmedabad offers active surveillance as a genuine first-line option for appropriately selected patients
What is radical prostatectomy and what are the functional outcomes?
Radical prostatectomy removes the entire prostate and seminal vesicles. Key functional outcomes are urinary continence (most men achieve continence by 12 months; approximately 10 to 15 percent have persistent significant leakage) and erectile function (preserved in 50 to 70 percent of men with bilateral nerve-sparing, depending on age and pre-operative function). At EPIC Multispecialty Hospital, Ahmedabad, laparoscopic and robotic prostatectomy with nerve-sparing technique optimise these outcomes.
What is androgen deprivation therapy (ADT) for prostate cancer?
ADT reduces testosterone to castrate levels — either by LHRH agonists (leuprolide, goserelin — monthly, 3-monthly, or 6-monthly injections) or antagonists (degarelix, relugolix — no testosterone flare). ADT is used for locally advanced, node-positive, and metastatic prostate cancer. Side effects include hot flushes, fatigue, loss of libido, erectile dysfunction, bone density reduction, and metabolic syndrome — managed with monitoring and specific interventions at EPIC Hospital Ahmedabad.
What is the treatment for metastatic prostate cancer?
Metastatic hormone-sensitive prostate cancer (mHSPC) is treated with ADT combined with docetaxel chemotherapy or novel AR pathway inhibitors (enzalutamide, abiraterone, apalutamide — LATITUDE, CHAARTED, STAMPEDE trials). Castration-resistant prostate cancer (CRPC) is treated with docetaxel, cabazitaxel, enzalutamide, abiraterone, PARP inhibitors (BRCA-mutated), or Ra-223 for bone-dominant disease.
Is robotic prostate cancer surgery available at EPIC Hospital Ahmedabad?
Yes. Robotic-assisted laparoscopic radical prostatectomy (RALP) is available at EPIC Multispecialty Hospital, Ahmedabad, for localised prostate cancer. Robotic surgery provides 3D vision, 10-times magnification, and wristed instrument articulation for precise neurovascular bundle and apical dissection — optimising continence and potency outcomes.
Should all men over 50 in Ahmedabad have a PSA test?
PSA screening involves a nuanced risk-benefit discussion. Screening detects prostate cancer earlier and reduces prostate cancer mortality, but also detects cancers that would never have caused harm — leading to potential over-treatment. At EPIC Multispecialty Hospital, Ahmedabad, we recommend shared decision-making about PSA testing for men over 50, or over 45 with a family history of prostate cancer, with honest discussion of the benefits and limitations of screening.
What is the cost of prostate cancer treatment in Ahmedabad at EPIC Hospital?
Prostate cancer treatment costs at EPIC Multispecialty Hospital, Ahmedabad, vary by approach — active surveillance monitoring, laparoscopic or robotic prostatectomy, radiotherapy, and systemic therapy (ADT, docetaxel, novel AR inhibitors) each carry different costs. Insurance covers most prostate cancer treatment modalities. Contact our patient services team for procedure-specific current pricing.
Prostate Cancer Treatment in Ahmedabad — EPIC Multispecialty Hospital
Prostate cancer treatment at EPIC Multispecialty Hospital, Ahmedabad, is guided by the oncological evidence — active surveillance where appropriate, radical prostatectomy or radiotherapy where curative treatment is indicated, and advanced systemic therapy for metastatic disease — through a uro-oncology programme that takes the decision of whether and when to treat as seriously as the decision of how.
Book a prostate cancer consultation online, call EPIC Multispecialty Hospital Ahmedabad today, WhatsApp your PSA results and MRI prostate for initial review, or visit us directly — and get prostate cancer management built on what the evidence shows is right for your cancer risk category.